Referral program
Takeover – Shockwave Medical ($SWAV) Being Bought by Johnson & Johnson ($JNJ) for $335

DKI originally recommended Shockwave Medical ($SWAV) in December when the stock was at $190. A key part of our positive thesis on the stock was our expectation of a takeover at > $300.

This morning, Johnson & Johnson ($JNJ) announced a deal to buy $SWAV for $335 in cash.

I’d like to thank cardiologist and DKI Board Member, Dr. Paul Thompson who suggested the idea to me, and interventional cardiologist, Dan Fram, who kindly explained the technology to DKI subscribers during a January webinar. Their work enabled DKI subscribers to understand the medical implications well enough to be comfortable taking larger and very profitable positions.

DKI subscribers have made 76% in under 4 months. If you know anyone who would value the kind of work we’re doing here at DKI, please refer them here. If they subscribe, we’ll extend your subscription by a month. with any questions.

Information contained in this report, and in each of its reports, is believed by Deep Knowledge Investing (“DKI”) to be accurate and/or derived from sources which it believes to be reliable; however, such information is presented without warranty of any kind, whether express or implied.  DKI makes no representation as to the completeness, timeliness, accuracy or soundness of the information and opinions contained therein or regarding any results that may be obtained from their use. The information and opinions contained in this report and in each of our reports and all other DKI Services shall not obligate DKI to provide updated or similar information in the future, except to the extent it is required by law to do so. 


The information we provide in this and in each of our reports, is publicly available. This report and each of our reports are neither an offer nor a solicitation to buy or sell securities. All expressions of opinion in this and in each of our reports are precisely that. Our opinions are subject to change, which DKI may not convey. DKI, affiliates of DKI or its principal or others associated with DKI may have, taken or sold, or may in the future take or sell positions in securities of companies about which we write, without disclosing any such transactions.


None of the information we provide or the opinions we express, including those in this report, or in any of our reports, are advice of any kind, including, without limitation, advice that investment in a company’s securities is prudent or suitable for any r investor. In making any investment decision, each investor should consult with and rely on his or its own investigation, due diligence and the recommendations of investment professionals whom the investor has engaged for that purpose. 


In no event shall DKI be liable, based on this or any of its reports, or on any information or opinions DKI expresses or provides for any losses or damages of any kind or nature including, without limitation, costs, liabilities, trading losses, expenses (including, without limitation, attorneys’ fees), direct, indirect, punitive, incidental, special or consequential damages.


Leave a Comment

Recent Blogs

Invite & Earn

Signup to start sharing your link
background banner image
loading gif

Available Coupon